Combination therapy effective for higher-risk MDS/AML patients
A phase two study investigating the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective front-line treatment for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.
Myelodysplastic syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells, resulting in abnormal (blast...
Antifibrotic agent showing benefits for advanced myelofibrosis
A study investigating the potential of the antifibrotic compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in...
Efforts to improve treatments for melanoma of the eye
Although primary uveal melanoma can be effectively treated with radiation or surgery, patients with metastatic disease — or those at high...
Health research: Pay now or pay later
By reducing investments in medical research, any short-term savings will prove to be very costly in the long run — and not just financially. That was the crux of the argument made by Ethan Dmitrovsky, M.D., in an opinion piece recently published in the Pittsburgh Post-Gazette.
“In recent years, America has reduced its commitment to developing new treatments and cures. If we continue down this path, short-term savings will be eclipsed...
Targeting microRNA may benefit some ovarian and breast cancer patients
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it’s among the most frequent chromosomal aberrations seen in many...
MD Anderson, Intrexon and ZIOPHARM connect on immunotherapy
Biotech companies Intrexon and ZIOPHARM Oncology have licensed unique MD Anderson immunotherapy technology, creating an...